Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL LEVINE

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1740252048
CMS profile
123914
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$5,218.33

122 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL LEVINE

NPI 1740252048 · CMS profile ID 123914

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740252048?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL LEVINE, NPI 1740252048, CMS profile ID 123914. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740252048?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MICHAEL LEVINE, NPI 1740252048, CMS profile ID 123914. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740252048?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MICHAEL LEVINE, NPI 1740252048, CMS profile ID 123914, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 122 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1740252048?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

122 matching records · $5,218.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 122 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 122.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $1.8108/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721416503 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.1208/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737563869 CMS
Daiichi Sankyo Inc. $11.4208/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739495037 CMS
Daiichi Sankyo Inc. $2.6308/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739509781 CMS
Merck Sharp & Dohme Corporation $17.6508/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747635665 CMS
Amgen Inc. $26.2508/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229671 CMS
Amgen Inc. $26.1108/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741420279 CMS
Amgen Inc. $19.5108/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229687 CMS
AstraZeneca Pharmaceuticals LP $20.8107/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735939559 CMS
Otsuka America Pharmaceutical, Inc. $2.3807/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748746597 CMS
Otsuka America Pharmaceutical, Inc. $21.4107/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748746601 CMS
Lilly USA, LLC $22.6107/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728567247 CMS
Daiichi Sankyo Inc. $2.6207/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739493639 CMS
Daiichi Sankyo Inc. $16.4007/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739493649 CMS
GlaxoSmithKline, LLC. $15.1407/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738492141 CMS
Horizon Therapeutics plc $2.3807/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721416497 CMS
Horizon Therapeutics plc $15.7807/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721416499 CMS
AstraZeneca Pharmaceuticals LP $24.4107/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735907229 CMS
Merck Sharp & Dohme Corporation $19.4307/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747716035 CMS
Amgen Inc. $7.9007/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229685 CMS
AstraZeneca Pharmaceuticals LP $19.9507/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735807883 CMS
Amgen Inc. $17.5906/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229669 CMS
Otsuka America Pharmaceutical, Inc. $3.2406/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748746591 CMS
Otsuka America Pharmaceutical, Inc. $18.1306/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748746595 CMS
Lilly USA, LLC $23.0306/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728570669 CMS
Horizon Therapeutics plc $2.2306/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721416493 CMS
Horizon Therapeutics plc $14.7206/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721416495 CMS
Amgen Inc. $27.3806/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229701 CMS
AstraZeneca Pharmaceuticals LP $21.0006/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735786813 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.8206/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737563867 CMS
Amgen Inc. $13.8605/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229681 CMS
Janssen Pharmaceuticals, Inc $17.4705/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719312063 CMS
Amgen Inc. $22.1405/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229699 CMS
AstraZeneca Pharmaceuticals LP $16.8805/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736335269 CMS
GlaxoSmithKline, LLC. $21.4905/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738491961 CMS
Horizon Therapeutics plc $14.9404/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721416489 CMS
Horizon Therapeutics plc $8.9604/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721416491 CMS
Amgen Inc. $25.0304/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229667 CMS
Amgen Inc. $8.0104/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229697 CMS
Amgen Inc. $18.1304/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229663 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.2504/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737563865 CMS
GENZYME CORPORATION $18.8904/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744049747 CMS
Horizon Therapeutics plc $13.6004/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721416487 CMS
Amgen Inc. $24.4004/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229665 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.8304/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720565599 CMS
Horizon Therapeutics plc $15.9204/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721416485 CMS
AstraZeneca Pharmaceuticals LP $17.4803/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735803771 CMS
Amgen Inc. $15.2303/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229661 CMS
Amgen Inc. $20.2803/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229679 CMS
Amgen Inc. $18.0703/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741229683 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,701.13 110
PY2020 $5,218.33 122
PY2021 $2,349.38 132
PY2022 $1,728.33 104
PY2023 $3,400.82 124
PY2024 $3,244.37 173
PY2025 $3,033.30 141

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $219,472.34 20
PY2024 Principal investigator $131,939.15 35
PY2023 Principal investigator $365,370.61 45
PY2022 Principal investigator $81,124.78 13
PY2021 Principal investigator $12,247.60 3
PY2020 Principal investigator $5,792.70 6
PY2019 Recipient $1,199.21 15
PY2019 Principal investigator $28,976.90 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $22,500.00 10/15/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER
Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) No dispute reported 06/30/2026 1185548095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $21,248.30 09/17/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,585.00 09/17/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523793
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,000.00 09/17/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,000.00 09/17/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 09/17/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523799
Principal investigator 1 CSL Behring $5,841.00 09/17/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665851
Principal investigator 1 CSL Behring $16.71 08/05/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665985
Principal investigator 1 CSL Behring $8,761.50 07/16/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665847
Principal investigator 1 CSL Behring $894.52 06/26/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $700.00 06/02/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,250.00 06/02/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523771
Principal investigator 1 CSL Behring $367.52 04/28/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665955
Principal investigator 1 CSL Behring $324.32 04/24/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665953
Principal investigator 1 CSL Behring $3,370.50 04/16/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665845
Principal investigator 1 CSL Behring $16.71 04/09/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665893
Principal investigator 1 CSL Behring $423.76 03/31/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665873
Principal investigator 1 CSL Behring $604.78 02/28/2025 Non-covered Recipient Entity
Amicis Research Center
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665877
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,282.20 02/26/2025 Non-covered Recipient Entity
AMICIS RESEARCH CENTER
A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease No dispute reported 06/30/2026 1185548093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $130,285.52 02/21/2025 Non-covered Recipient Entity
Amicis Research Center
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215523753